CDH, an alternative asset management firm, led a $108m Series C funding round in IASO Biotherapeutics, a developer of cancer biotherapeutics. Other investors include CCB International, Everbright, Co-Stone Capital, CNCB Capital, Plaisance Capital and GL Ventures. “The proceeds raised will enable us to advance our innovative pipeline and consolidate our strategic positioning and advantages in immuno-oncology and autoimmune diseases. With an innovative and pioneering spirit and strong execution ability, our team will continue to commit ourselves to bringing life-changing therapies to patients worldwide," Wen Wang, IASO Bio CEO & CMO.